Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Brainstorm Cell Therapeutics Inc. BCLI
$2.83
-$0.03 (-1.05%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
106045949.00000000
-
week52high
4.70
-
week52low
1.09
-
Revenue
0
-
P/E TTM
-14
-
Beta
-0.37681600
-
EPS
-0.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | Hold | 05 февр 2021 г. |
| H.C. Wainwright | Buy | 15 мая 2018 г. | |
| Maxim Group | Buy | Buy | 17 авг 2017 г. |
| HC Wainwright & Co. | Buy | 15 мая 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lindborg Stacy | A | 60000 | 35000 | 07 дек 2022 г. |
| Lebovits Chaim | A | 187110 | 31185 | 18 сент 2022 г. |
| FRENKEL JACOB A | A | 50000 | 50000 | 06 апр 2022 г. |
| Kern Ralph Dr. | A | 223310 | 35885 | 06 мар 2022 г. |
| Polverino Anthony J. | A | 25960 | 3882 | 01 февр 2022 г. |
| ARBEL IRIT | A | 25333 | 25333 | 15 дек 2021 г. |
| Yablonka Uri | A | 13333 | 13333 | 15 дек 2021 г. |
| Almenoff June Sherie | A | 6000 | 2000 | 15 дек 2021 г. |
| Polverino Anthony J. | A | 22078 | 2000 | 15 дек 2021 г. |
| TAUB MALCOLM S | A | 77332 | 12000 | 15 дек 2021 г. |
Новостная лента
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update
PRNewsWire
09 мая 2023 г. в 06:00
NEW YORK , May 9, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the First Quarter ended March 31, 2023, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, May 15th.
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
PRNewsWire
21 мар 2023 г. в 08:18
NEW YORK , March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Thursday, March 30th.
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
PRNewsWire
07 ноя 2022 г. в 16:10
NEW YORK , Nov. 7, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, November 14, 2022.
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Seeking Alpha
21 авг 2022 г. в 03:57
Brainstorm Cell Therapeutics is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. NurOwn's mechanism of action relies on bringing down neuroinflammation and altering glial activity, a recipe that seems to be a winner in neurodegenerative diseases.
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
PRNewsWire
01 авг 2022 г. в 06:00
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.